H. Lundbeck (HLUN-B.CO) Stock Analysis & AI Equity Report

Drug Manufacturers - Specialty & Generic DKK Explore free reports

H. Lundbeck (HLUN-B.CO) overview

H. Lundbeck (HLUN-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, H. Lundbeck reported revenue of DKK 24,351m and operating profit of DKK 6,343m; the year-end share price was 43.16 DKK and market capitalisation was DKK 42,821m. H. Lundbeck is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get H. Lundbeck's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueDKK 24,903mFY 2025
Share price43.16 DKKFY 2025 year end
RevenueDKK 24,351mFY 2025
Operating profitDKK 6,343mFY 2025
Net earningsDKK 3,192mFY 2025
Market capitalisationDKK 42,821mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About H. Lundbeck

H. Lundbeck A/S is a biopharmaceutical company focused on brain health. It researches, develops, manufactures and commercializes medicines for neurological and psychiatric disorders, with strengths in psychiatry and neurology and an expanding portfolio in neuro-specialty and neuro-rare diseases. The company also works with external partners to advance research and develop new treatments.

Generate the H. Lundbeck report

H. Lundbeck is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for H. Lundbeck and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on H. Lundbeck

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.